Feed BROOKS.NS
BR

Brooks Laboratories Limited BROOKS.NS · NSE

₹65.70 -0.39% (-₹0.26)

Summary

60 / 100 · Bulios Score

What speaks for it

  • Out of every 100 INR of revenue, 16 INR is left as net profit.
  • Revenue grew by 11% a year over the last 3 years.

What to watch

  • The share price is above the Bulios Fair Price.
  • It reports a profit, yet spends more cash than it brings in.
  • It earns only 3.1 INR a year on every 100 INR of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Current price ₹65.7
P/E today 14.6
Drug Manufacturers - Specialty & Generic industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 14.6 INR for 1 INR of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (INR)

Diluted EPS (INR)

Revenue grew by 2.2% a year over 5 years. Over the last 3 years it grew by 11% a year.

Growth in detail

Does it make money?

Reasonably

Where 100 INR of revenue goes

Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 INR

Out of every 100 INR of revenue, 16 INR is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It has no debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy